Brain Blogger Home
  • Home
  • About
    • Editor's Note
    • Contributors
  • Advertise
  • Archives
    • By Author
    • By Topic
    • By Year
    • By Month
  • Contact
  • Contribute
  • Topics
    • Popular
    • Series
    • Video
    • Carnivals
  • Sitemap
  • Subscribe
  • Neuroscience & Neurology
  • Psychology & Psychiatry
  • Health & Healthcare
  • More >>
    • BioPsychoSocial Health
    • Complementary & Alternative Medicine
    • Drugs & Clinical Trials
    • History of Medicine
    • Law & Politics
    • Living with a Brain Disorder
    • Opinion
    • Site News
    • Stigmatization
Brain Blogger RSS Feed

Brain Blogger Feed - 3500+ Readers

Follow BB:

Brain Blogger on FaceBook Brain Blogger on twitter Brain Blogger on Flickr Brain Blogger on YouTube
Opinion
August 12, 2005

Polypharmacy: What Cost in Morbidity and Mortality?

By Ray McIntyre | No Comments | Share | Print | Email | Tweet | Like | 1+

Opinion2.jpgA paper by Dr. Charles Sullivan, presented by the author at the 2003 New England Forensic Sciences Conference at Colby College: It is common practice in Medicine to put patients on combinations of drugs. The vast majority of these combinations of drugs (especially where 3 or more drugs are involved) have never been studied at all, let alone in double-blind trials ( with the exception of Oncology/AIDS treatment, where the toxicity of the drugs demands study); yet it is frequent practice to prescribe these multiple-drug combinations.

It is well accepted in pharmacology that it is scientifically impossible to accurately predict the side effects or clinical effects of a combination of drugs without studying that particular combination of drugs in test subjects. Knowledge of the pharmacologic profiles of the individual drugs in question does not in any way assure accurate prediction of the side effects of combinations of those drugs, especially when they have different mechanisms of action, which is very common because polypharmacy is most often prescribed to patients with “multiple illnesses”. More than 100,000 patients in this country die from identified adverse drug reactions (perhaps the 4th to 6th leading cause of death in the U.S.)[1] The number who die as a consequence of polypharmacy is, to my knowledge, unknown.

The argument that the prescribing of drugs is the “Art” of Medicine is not valid in defending polypharmacy, because drugs are developed (indications, dose and administration, etc.) and approved through a “scientific” process (double-blind, placebo-controlled studies). The fact that the medicines are often prescribed for “different conditions” is irrelevant (especially to the patient’s physiology). The idea that ” we are doing the best we can “, a frequent defense of Polypharmacy, does not in any way uphold a scientific argument in favor of it. (We are, indeed, trying the best we can, with tools which do not improve at the rate we would wish!) The fact that “there is a limit to how much research can be done” in no way makes the research unnecessary in order to predict the side effects of specific combinations of drugs.

It has been said in the past that less than 30% of medical practice was backed by controlled studies.[2,3] Has this changed? How do we know? Are we looking closely enough at our way of practicing Medicine? Can the use of unstudied polypharmacy really be considered evidence-based, “scientific” Medicine? Can the Pathology community help initiate meaningful debate regarding this subject at a level that will produce more widespread awareness?

Charles Sullivan, D.O.

“Science progresses, funeral by funeral.” – Max Planck

1. Incidence of Adverse Drug Reactions in Hospitalized Patients. JAMA. 1998;279:1200-1205

2. Office of Technology Assessment: Assessing the efficacy and safety of medical technologies. U.S. Government Printing Office, Washington, 1978

3. Smith R: Where is the wisdom? The poverty of medical evidence. BMJ 1991;303:798

4. “…only about 15% of medical interventions are supported by solid scientific evidence; in other words, eighty-five percent are not.” Smith, R (editor of British Medical Journal). The ethics of ignorance. Journal of Medical Ethics. 1992;18:117

Additional References

Daubert v. Merrel Dow Pharmaceuticals 509 U.S. 579 (1993), 509, 579.

Goodstein, D. 2000. How Science Works. In U.S. Federal Judiciar Reference Manual on Evidence, pp. 66-72.

Horrobin, D.F. 1990. The philosophical basis of peer review and the suppression of innovation. J. Am. Med. Assoc. 263:1438-1441.

Horrobin, D.F. 1996. Peer review of grant applications: A harbinger for mediocrity in clinical research? Lancet 348:1293-1295.

Horrobin, D.F. 1981-1982. Peer review: Is the good the enemy of the best? J. Res. Commun. Stud. 3:327-334.

Horrobin, D.F. 2000. Innovation in the pharmaceutical industry. J. R. Soc. Med. 93:341-345.

Rothwell, P.M. and Martyn, C.N. 2000. Reproducibility of peer review in clinical neuroscience: Is agreement between reviewers any greater than would be expected by chance alone? Brain 123:1964-1969.

Ray McIntyre

Mr. McIntyre is a former librarian who spent many years in social justice.

Related Articles

  • Ethnic Medicine – Beyond Bidil
  • Drugs and Pharmacology, Sixth Edition
  • Drugs and Pharmacology, First Edition
  • The Curse of the Nocebo Effect
  • Are Generic Drugs Really Equivalent to Brand Name Drugs?
  • How Strong is Your Evidence?
  • Why People Stop Taking Anti-Depressants: Part 1

No Responses

Leave a Reply

Click here to cancel reply.

Subscribe without commenting


Popular Posts

  • The Love Drug
  • Women After Sex
  • Fatty Acids and Suicide Risk
  • Mind Games - Science's Attempts at Thought Control
  • Risks of Personalized Medicine
  • Mental Health Disorders Prevalent Among Youth Worldwide
  • Is Giftedness Nothing More than Good Genes?
  • The Many Emerging Roles of Astrocytes
  • Behind the Masks - The Mysteries of Dissociative Identity Disorder
  • The NeuroSocial Network

Future Posts

  • The Brain’s Buying Power

Latest Posts

  • Aging Intelligently
  • A Nicotine Patch a Day Keeps the Cognitive Impairment Away
  • The Many Emerging Roles of Astrocytes
  • Diabetes Impairs Cognition
  • Media Violence Leads to Real Violence
  • Intelligence – Are You Holding Back Your Brain?
  • Childhood Aggression Predicts Health Care Use Later in Life
  • The Brain’s Border Patrol – Blood Brain Barrier
  • Risks of Personalized Medicine
  • BED-head and Obesity – Food for Thought

Comments

  • : This article had great info on
  • peter: I also see things the same way
  • Scapadas Amorosas: Lets patent it, package, marke
  • Emily Haines, MSc, PhD student: Thanks for your comments, Matt
  • Emily Haines, MSc, PhD student: Thanks for your comments and s
  • Alex: While we have our eyes glued t
  • Richard Kensinger, MSW: Carla,You are absolutely c
  • Soraya L. Valles: I'm interested in astrocytes.
  • Raymond Tallis: Dear Kitty, I have come to you
  • Steven: After smoking for 17 years dai
  • Matt: I'm just interested in hearing
  • Carla Easley: If everyone adopted the "Growt
Sponsored Links

GNLD, memory improvement, web design brisbane, Autism News Blog, Pharmaceutical Training, Neurotherapist, HGH, Rollup Banner Stands , Buy Celebrex , AtomicPR , treatment centers , Lab Work California

Copyright © 2005-2012 Brain Blogger sponsored by Global Neuroscience Initiative Foundation (GNIF). All Rights Reserved.
Disclaimer | Privacy Policy | Feed | Log in | ISSN 1931-6224 | 0.844s
9rules Network Member